NC
PRCT icon

nVerses Capital’s Procept Biorobotics PRCT Stock Holding History

nVerses Capital’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
+9,484
New +$237K 0.33% 172
2024
Q3 		– Sell
-2,400
Closed -$147K – 1324
2024
Q2 		$147K Buy
2,400
+1,800
+300% +$107K 0.09% 337
2024
Q1 		$29.7K Buy
+600
New +$28.6K 0.07% 346

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

nVerses Capital's PRCT Position: Q2 2026 in Review

nVerses Capital opened a new position in Procept Biorobotics (PRCT) in Q2 2026: 9,484 shares worth $214K. The stake represents 0.33% of the portfolio and ranks #172 among its holdings. This is a return to the name: nVerses Capital previously reported a position in PRCT as recently as Q2 2024.

nVerses Capital first reported a position in PRCT in Q1 2024 and has held it in 3 quarters since. 253 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • nVerses Capital held 9,484 shares of Procept Biorobotics worth $214K as of Q2 2026.
  • Procept Biorobotics was a new nVerses Capital position in Q2 2026.
  • Procept Biorobotics made up 0.33% of nVerses Capital's portfolio in Q2 2026, its #172 holding.
  • nVerses Capital first reported a position in Procept Biorobotics in Q1 2024 and has held it in 3 quarters since.
  • 253 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.